Tvardi Therapeutics, Inc. (TVRD)
NASDAQ: TVRD · Real-Time Price · USD
26.25
+0.20 (0.77%)
At close: May 9, 2025, 4:00 PM
25.61
-0.64 (-2.44%)
After-hours: May 9, 2025, 4:05 PM EDT
Company Description
Tvardi Therapeutics, Inc. operates as a biotechnology company that develops medicines for cancer, chronic inflammation diseases, and fibrosis diseases.
It develops inhibitors of STAT3, a molecule implicated in the initiation and progression of cancer and fibrosis.
Its pipeline includes TTI-101, a small-molecule inhibitor of signal transducers and activators of transcription; and TTI-109, a STAT3 inhibitor for clinical use, including tolerability, bioavailability, and potency.
Tvardi Therapeutics, Inc. was incorporated in 2017 and is based in Sugar Land, Texas.
Tvardi Therapeutics, Inc.
| Country | United States |
| Founded | 2017 |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | Imran Alibhai |
Contact Details
Address: 3 Sugar Creek Center Boulevard, Suite 525 Sugar Land, Texas 77478 United States | |
| Phone | 832-413-1362 |
| Website | tvarditherapeutics.com |
Stock Details
| Ticker Symbol | TVRD |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Reporting Currency | USD |
| CIK Code | 0001742947 |
| CUSIP Number | 140755307 |
| ISIN Number | US1407553072 |
Key Executives
| Name | Position |
|---|---|
| Imran Alibhai | Chief Executive Officer |
| Dan Conn | Chief Financial Officer |